Enabling Technologies For Design And Delivery Of Novel Vaccines Against Infectious Diseases And Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$925,346.00
Summary
This grant will support research necessary to develop the next generation of vaccines. These will combat diseases caused by bacteria and viruses and can also be used to fight cancer. The broad range of application is made possible through the incorporation of simple molecular features that activate the immune system. The intellectual property that has been developed is protected by a patent portfolio some patents of which are already licenced to the pharmaceutical industry.
Dengue Fever Vaccine: Towards Low Cost Production And Delivery
Funder
National Health and Medical Research Council
Funding Amount
$612,039.00
Summary
With rising populations and a warming climate mosquito borne viral diseases will become more prevalent and low-cost vaccine production & delivery systems will become increasingly important. Here a microalgae based vaccine production platform will be coupled to proven Nanopatch & low cost oral vaccine delivery. The focus is on a Dengue virus vaccine, as Dengue causes 400 million infections & 100 million symptomatic cases annually.
Development Of A Self-adjuvanting Mucosal Vaccine Candidate Against Group A Streptococcus Using Lipid Core Technology
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
Novel developments in drug/vaccine delivery are clearly to have enormous economic and social impacts. My research aim is to rationally design and develop vaccines against relevant diseases. By understanding the mechanism of protection against diseases, development of novel vaccines for the treatment of many diseases can be achieved. This would contribute enormously to the betterment of public health.
OptiMalVax: Optimizing A Deployable High Efficacy Malaria Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$494,618.00
Summary
In this proposal, a consortium comprising many of the leading malariologists, vaccine researchers and product developers in Europe, USA, Australia and Africa will collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates against malaria.
Hepatitis C Vaccines: Preclinical To Clinical Development
Funder
National Health and Medical Research Council
Funding Amount
$474,244.00
Summary
Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infections each year. Treatments currently available for hepatitis C are effective but also associated with significant side effects and expensive. The economic and health burden of hepatitis C infection and the high costs of emerging antiviral therapies makes the development of an effective vaccine for HCV imperative. This project aims to develop a vaccine for the p ....Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infections each year. Treatments currently available for hepatitis C are effective but also associated with significant side effects and expensive. The economic and health burden of hepatitis C infection and the high costs of emerging antiviral therapies makes the development of an effective vaccine for HCV imperative. This project aims to develop a vaccine for the prevention of hepatitis C infection.Read moreRead less
Developing A Vaccine To Protect Against Hypervirulent Strains Of Group A Streptococcus
Funder
National Health and Medical Research Council
Funding Amount
$536,850.00
Summary
Epidemic invasive GAS disease is associated with the emergence of the globally disseminated M1T1 clone and is linked to the mutation in the CovR/S regulator. This mutation leads to over- expression of SpyCEP and inhibits recruitment of neutrophils to the site of infection. Inclusion of an immunogenic fragment of SpyCEP into our current vaccine would enhance its efficacy and lead to the development of a vaccine with a wider coverage and better protective efficacy against hypervirulent GAS strains
A Universal Prophylactic Vaccine For Hepatitis C Virus
Funder
National Health and Medical Research Council
Funding Amount
$643,337.00
Summary
Hepatitis C Virus (HCV) infects 200 million people world wide. An effective vaccine to prevent HCV is urgently needed but must afford protection against the 7 diverse genotypes. In this project grant we aim to further define the quality of the immune response that is generated by a novel HCV vaccine candidate that generates pan-genotypic immunity, its unique structural features, and methods of manufacturing so that it can be tested in a future phase I human clinical trial.
This an integrated program of basic research on antigen discovery and immune mechanisms, and preclinical research on novel vaccine platforms, formulations or delivery systems for the rational design and clinical testing of a next generation vaccine against malaria. This interdisciplinary research fosters strong national and international links and offers the potential for significant economic benefit to Australia.
A Novel Vaccine Formaultion To Prevent Birth Defects
Funder
National Health and Medical Research Council
Funding Amount
$530,922.00
Summary
Congenital cytomegalovirus (CMV) infection is one of the TORCH infections (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex) and is one of major cause of birth defects. Transmission of CMV infection from mother to unborn babies can lead to deafness, blindness, small head syndrome (microcephaly), seizures and mental retardation. There is an urgent need to develop an effective vaccine against CMV. This project is aiming to develop a novel CMV vaccine formulation for clinical testing in ....Congenital cytomegalovirus (CMV) infection is one of the TORCH infections (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex) and is one of major cause of birth defects. Transmission of CMV infection from mother to unborn babies can lead to deafness, blindness, small head syndrome (microcephaly), seizures and mental retardation. There is an urgent need to develop an effective vaccine against CMV. This project is aiming to develop a novel CMV vaccine formulation for clinical testing in humans.Read moreRead less